Hence, elucidating the main immune escape mechanism of lung adenocarcinoma can greatly reduce the risk of PD-1/PD-L1 blockade, identify new immune targets and broaden the therapeutic scope of immune checkpoint inhibitors. Here, CD274 is linked to lung adenocarcinoma.